var data={"title":"Pentoxifylline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentoxifylline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6752?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentoxifylline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentoxifylline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pentoxifylline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208251\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pentoxifylline SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208296\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Viscosity Reducer Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208255\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intermittent claudication:</b> Oral: 400 mg 3 times daily; maximal therapeutic benefit may take 2 to 4 weeks to develop; recommended to maintain therapy for at least 8 weeks. May reduce to 400 mg twice daily if GI or CNS side effects occur; discontinue if side effects persist. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Use for the treatment of intermittent claudication refractory to exercise therapy (and smoking cessation) has been discouraged by The American College of Chest Physicians (ACCP) (Guyatt, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe alcoholic hepatitis (Maddrey Discriminant Function [MDF] score &ge;32, especially when corticosteroids contraindicated) (off-label use):</b> Oral: 400 mg 3 times daily for 4 weeks (O&rsquo;Shea, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous leg ulcer (off-label use):</b> Oral: 400 mg 3 times daily (with compression therapy) (Jull, 2002; Robson, 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208256\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7679765\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer's labeling: CrCl &lt;30 mL/minute: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aronoff, 2007: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: 400 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10-50 mL/minute: 400 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL minute: 400 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: supplemental postdialysis dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 400 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Paap, 1996: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate renal impairment (CrCl ~60 mL/minute): 400 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe renal impairment (CrCl ~20 mL/minute): 400 mg once daily; further reduction may be required; Paap suggests 200 mg once daily, but with current products (extended or controlled release; unscored) may require adaptation to 400 mg once every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370162\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208229\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208215\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208232\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food. Swallow whole; do not chew, crush, or divide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208231\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intermittent claudication:</b> Treatment of intermittent claudication on the basis of chronic occlusive arterial disease of the limbs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: May improve function and symptoms, but not intended to replace more definitive therapy. <b>Note:</b> The American College of Chest Physicians (ACCP) discourages the use of pentoxifylline for the treatment of intermittent claudication refractory to exercise therapy (and smoking cessation) (Guyatt, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470479\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Severe alcoholic liver disease; Venous leg ulcers (with compression therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208304\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentoxifylline may be confused with tamoxifen </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TRENtal may be confused with Bentyl, TEGretol, Trandate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208222\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Nausea (2%), vomiting (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, angina pectoris, anorexia, anxiety, aplastic anemia, aseptic meningitis, bloating, blurred vision, cardiac arrhythmia, chest pain, cholecystitis, confusion, conjunctivitis, constipation, decreased serum fibrinogen, depression, dysgeusia, dyspnea, edema, epistaxis, eructation, flatulence, flu-like symptoms, hallucination, hepatitis, hypotension, increased liver enzymes, jaundice, laryngitis, leukemia, leukopenia, malaise, nail disease (brittle fingernails), nasal congestion, otalgia, pancytopenia, pruritus, purpura, scotoma, seizure, sialorrhea, skin rash, sore throat, tachycardia, thrombocytopenia, tremor, urticaria, weight changes, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208235\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Patients previously exhibiting intolerance to pentoxifylline, xanthines (eg, caffeine, theophylline), or any component of the formulation; recent cerebral and/or retinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Acute MI, severe coronary artery disease when myocardial stimulation might prove harmful, peptic ulcers (current or recent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208219\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/anaphylactoid reactions: Discontinue at first sign of anaphylaxis or anaphylactoid reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; the bioavailability of pentoxifylline and metabolite I is increased. Has not been studied in patients with severe hepatic disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; bioavailability of active metabolite V may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly due to the potential for cardiac, hepatic, or renal impairment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208290\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208224\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9757&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentoxifylline may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Pentoxifylline may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Pentoxifylline may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): Pentoxifylline may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Pentoxifylline may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Pentoxifylline may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208246\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may decrease rate but not extent of absorption. Pentoxifylline peak serum levels may be decreased if taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208226\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208238\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Information related to use in pregnant women has not been located. Pentoxifylline may be used to test sperm viability when evaluating nonfertile males (ASRM, 2012). It has also been evaluated for the treatment of infertility due to endometriosis, but use for this purpose is not currently recommended (Lu, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21279941\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pentoxifylline and its metabolites are excreted into breast milk. Five nursing women (~6 weeks postpartum) were given a single dose of pentoxifylline 400 mg and maternal milk and serum samples were measured 2 and 4 hours later. The mean M/P ratio of pentoxifylline was 0.87 at 4 hours; actual milk concentrations ranged from below the limit of detection to 67.4 ng/mL. Three metabolites were also measured in breast milk, with mean M/P ratios ranging from 0.54-1.13 at 4 hours (Witter, 1985). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208239\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25315740\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function; hemoglobin/hematocrit in patients with risk factors for hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208218\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pentoxifylline increases blood flow to the affected microcirculation. Although the precise mechanism of action is not well-defined, blood viscosity is lowered, erythrocyte flexibility is increased, leukocyte deformability is increased, and neutrophil adhesion and activation are decreased. Overall, tissue oxygenation is significantly increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208234\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 2 to 4 weeks with multiple doses </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to multiple metabolites; undergoes extensive first-pass effect; Pentoxifylline undergoes reduction to metabolite I (active), and oxidation to form metabolite V (active) (Ward 1987); <b>Note: </b>Plasma concentrations of M-1 and M-V are 5 and 8 times greater, respectively, than pentoxifylline </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 24 to 48 minutes; Metabolites: 60 to 96 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (0% as unchanged, 50% to 80% as M-V metabolite, 20% as other metabolites); feces (&lt;4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208237\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Pentoxifylline ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $114.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208240\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agapurin (HU, PK, VN);</li>\n      <li>Ahapuryn (UA);</li>\n      <li>Angiopurin (HU);</li>\n      <li>Artal (FI);</li>\n      <li>Artelife (MX);</li>\n      <li>Cental (TW);</li>\n      <li>Cerator (MY, TH);</li>\n      <li>Ceretal (TW);</li>\n      <li>Chinotal (HU);</li>\n      <li>Circulaid (JO);</li>\n      <li>Clem (PY);</li>\n      <li>Dartelin (HR);</li>\n      <li>Duplat (MX);</li>\n      <li>Elorgan (ES);</li>\n      <li>Fixoten (MX);</li>\n      <li>Flexital CR (TH);</li>\n      <li>Fylin (TW);</li>\n      <li>Hemovas (ES);</li>\n      <li>Ipentol (TW, VN);</li>\n      <li>Kentadin (MX);</li>\n      <li>Nelorpin (ES);</li>\n      <li>Oxiflux (RO);</li>\n      <li>Oxopurin 400 SR (IL);</li>\n      <li>Penphylline (TW);</li>\n      <li>Pentamon (HR);</li>\n      <li>Pentilin (HR, LV);</li>\n      <li>Pentolin (BD);</li>\n      <li>Pentox (PH);</li>\n      <li>Pentox von ct (LU);</li>\n      <li>Pentoxal (PH);</li>\n      <li>Pentoxi (CH);</li>\n      <li>Pentoxifilina (CO);</li>\n      <li>Pentoxifyllin AL (HU);</li>\n      <li>Pentoxifyllin Pharmavit (HU);</li>\n      <li>Pentoxifyllin-B (HU);</li>\n      <li>Pentoxifyllin-ratiopharm (LU);</li>\n      <li>Pentoxin SR (KR);</li>\n      <li>Pentoxine (JO, QA);</li>\n      <li>Pentyllin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Perencal (KR);</li>\n      <li>Peridane (MX);</li>\n      <li>Pexal (BM, BZ, GY, SR);</li>\n      <li>Pexol (PE);</li>\n      <li>Platof (ID);</li>\n      <li>Profiben (MX);</li>\n      <li>Qiquan (CN);</li>\n      <li>Rentylin (LU);</li>\n      <li>Sufisal (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tarontal (GR, ID, TR);</li>\n      <li>Torental (BE, FR, LU);</li>\n      <li>Trenfyl (ID);</li>\n      <li>Trenlin (HK);</li>\n      <li>Trenlin SR (SG);</li>\n      <li>Trental (AE, AR, AT, AU, BB, BD, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, FI, GB, GT, GY, HK, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KR, KW, LB, LT, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SI, SK, SR, SV, SY, TH, TR, TT, TW, UA, UY, VE, YE);</li>\n      <li>Trental SR (EG);</li>\n      <li>Trental-400 (LK);</li>\n      <li>Vantoxyl (MX);</li>\n      <li>Vasolax (BD);</li>\n      <li>Vasonit (AT, RO);</li>\n      <li>Vasonit Retard (LV);</li>\n      <li>Vasopentox (PE);</li>\n      <li>Xipen (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff SC, Quinn FJ, Carpenter LS, et al, &ldquo;Effects of Pentoxifylline on Sputum Neutrophil Elastase and Pulmonary Function in Patients With Cystic Fibrosis: Preliminary Observations,&rdquo; <i>J Pediatr</i>, 1994, 125(6 Pt 1):992-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/7996376/pubmed\" target=\"_blank\" id=\"7996376\">7996376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berman W Jr, Berman N, Pathak D, et al, &ldquo;Effects of Pentoxifylline (Trental&reg;) on Blood Flow, Viscosity, and Oxygen Transport in Young Adults With Inoperable Cyanotic Congenital Heart Disease,&rdquo; <i>Pediatr Cardiol</i>, 1994, 15(2):66-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/7997416/pubmed\" target=\"_blank\" id=\"7997416\">7997416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12047963\"></a>Jull  A, Waters  J, and Arroll  B, &quot;Pentoxifylline for Treatment of Venous Leg Ulcers: A Systematic Review,&quot; <i>Lancet</i>, 2002, 359(9317):1550-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/12047963/pubmed\" target=\"_blank\" id=\"12047963\">12047963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu D, Song H, Li Y, et al, &quot;Pentoxifylline for Endometriosis,&quot; <i>Cochrane Database Syst Rev</i>, 2012, 1:CD007677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/22258970/pubmed\" target=\"_blank\" id=\"22258970\">22258970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luke DR, Rocci ML Jr, and Hoholick C, &quot;Inhibition of Pentoxifylline Clearance by Cimetidine,&quot; <i>J Pharm Sci</i>, 1986, 75(2):155-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/3958924/pubmed\" target=\"_blank\" id=\"3958924\">3958924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mauro VF, Mauro LS, and Hageman JH, &quot;Alteration of Pentoxifylline Pharmacokinetics by Cimetidine,&quot;  <i>Clin Pharmacol</i>, 1988,  28(7):649-54.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Shea R, Dasarathy S, McCullough A, et al, &ldquo;Alcoholic Liver Disease,&rdquo; <i>Hepatology</i>, 2010, 51(1):307-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/20034030/pubmed\" target=\"_blank\" id=\"20034030\">20034030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paap CM, Simpson KS, Horton MW, et al, &ldquo;Multiple-Dose Pharmacokinetics of Pentoxifylline and its Metabolites During Renal Insufficiency,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(7-8):724-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/8826548/pubmed\" target=\"_blank\" id=\"8826548\">8826548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentoxifylline. [prescribing information]. Morgantown, WV: Mylan; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of American Society for Reproductive Medicine, &quot;Diagnostic Evaluation of the Infertile Male: A Committee Opinion,&quot; <i>Fertil Steril</i>, 2012, 98(2):294-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/22698639/pubmed\" target=\"_blank\" id=\"22698639\">22698639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson MC, Cooper DM, Aslam R, et al, &ldquo;Guidelines for the Treatment of Venous Ulcers,&rdquo; <i>Wound Repair Regen</i>, 2006, 14(6):649-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/17199831/pubmed\" target=\"_blank\" id=\"17199831\">17199831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trental (pentoxifylline) [prescribing information]. Parsippany, NJ: Validus; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward A and Clissold SP, &ldquo;Pentoxifylline: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Its Therapeutic Efficacy,&rdquo; <i>Drugs</i>, 1987, 34(1):50-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/3308412/pubmed\" target=\"_blank\" id=\"3308412\">3308412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witter FR and Smith RV, &quot;The Excretion of Pentoxifylline and Its Metabolites Into Human Breast Milk,&quot; <i>Am J Obstet Gynecol</i>, 1985, 151(8):1094-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-drug-information/abstract-text/3985069/pubmed\" target=\"_blank\" id=\"3985069\">3985069</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9757 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F208251\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F208296\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F208255\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F208256\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7679765\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370162\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F208229\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F208215\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F208232\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F208231\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470479\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F208304\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F208222\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F208235\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F208219\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F208290\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F208224\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F208246\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F208226\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F208238\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21279941\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F208239\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25315740\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F208218\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F208234\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F208237\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F208240\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9757|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentoxifylline-patient-drug-information\" class=\"drug drug_patient\">Pentoxifylline: Patient drug information</a></li><li><a href=\"topic.htm?path=pentoxifylline-pediatric-drug-information\" class=\"drug drug_pediatric\">Pentoxifylline: Pediatric drug information</a></li></ul></div></div>","javascript":null}